Heteroaryl-substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine derivatives as potent and selective corticotropin-releasing factor receptor-1 antagonists.
Sabbatini
Fabio Maria
FM
Department of Medicinal Chemistry, Psychiatry Centre of Excellence for Drug Discovery (CEDD), Medicines Research Centre, GlaxoSmithKline SpA, Via A. Fleming 4, 37135 Verona, Italy. fabio.m.sabbatini@GSK.com
Di Fabio
Romano
R
St-Denis
Yves
Y
Capelli
Anna-Maria
AM
Castiglioni
Emiliano
E
Contini
Stefania
S
Donati
Daniele
D
Fazzolari
Elettra
E
Gentile
Gabriella
G
Micheli
Fabrizio
F
Pavone
Francesca
F
Rinaldi
Marilisa
M
Pasquarello
Alessandra
A
Zampori
Maria Grazia
MG
Di Felice
Pina
P
Zarantonello
Paola
P
Arban
Roberto
R
Perini
Benedetta
B
Vitulli
Giovanni
G
Benedetti
Roberto
R
Oliosi
Beatrice
B
Worby
Angela
A
D000818:Animals; D001007:Anxiety / Q000188:drug therapy* / Q000473:pathology; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D003863:Depression / Q000188:drug therapy* / Q000473:pathology; D015195:Drug Design; D008956:Models, Chemical; D011720:Pyrazoles / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D000099052:CRF Receptor, Type 1
D011720:Pyrazoles; D011743:Pyrimidines; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1; D003346:Corticotropin-Releasing Hormone